Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery

---

Zarei O., Benvenuti S., Ustun-Alkan F., Hamzeh-Mivehroud M., Dastmalchi S.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.142, sa.12, ss.2429-2446, 2016 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Derleme
• Cilt numarası: 142 Sayı: 12
• Basım Tarihi: 2016
• Doi Numarası: 10.1007/s00432-016-2214-4
• Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.2429-2446
• Anahtar Kelimeler: Cancer, Drug conjugate, Monoclonal antibody, Peptide, Target therapy, Tumor, Tyrosine kinase receptor, MACROPHAGE-STIMULATING PROTEIN, HEPATOCYTE GROWTH-FACTOR, DORIGINE NANTAIS RON, HUMAN MONOCLONAL-ANTIBODIES, COLORECTAL-CARCINOMA CELLS, RESISTANT PROSTATE-CANCER, HUMAN-HUMAN HYBRIDOMAS, INHIBITS TUMOR-GROWTH, HUMAN GASTRIC-CANCER, BREAST-CANCER
• İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Cancer is one of the most important life-threatening diseases in the world. The current efforts to combat cancer are being focused on molecular-targeted therapies. The main purpose of such approaches is based on targeting cancer cell-specific molecules to minimize toxicity for the normal cells. RON (Recepteur d'Origine Nantais) tyrosine kinase receptor is one of the promising targets in cancer-targeted therapy and drug delivery.